Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BIDIL vs ACETAMINOPHEN AND CODEINE PHOSPHATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination of isosorbide dinitrate (a nitric oxide donor) and hydralazine (a direct vasodilator). Isosorbide dinitrate relaxes vascular smooth muscle via NO-mediated c GMP production; hydralazine reduces peripheral resistance and may inhibit DNA synthesis in endothelial cells. Synergy enhances vasodilation and improves cardiac output.
Acetaminophen: centrally acting analgesic and antipyretic, possibly via inhibition of cyclooxygenase (COX) and modulation of cannabinoid receptors. Codeine: prodrug converted to morphine; mu-opioid receptor agonist.
Heart failure: treatment to improve survival, prolong time to hospitalization, and improve quality of life in self-identified black patients with heart failure (NYHA class III-IV) receiving standard therapy (diuretics, ACE inhibitors/ARBs, beta-blockers). Off-label: none significant.
Mild to moderate pain,Pain accompanied by fever
Isosorbide dinitrate 20 mg plus hydralazine 37.5 mg orally three times daily; titrate to target dose of isosorbide dinitrate 40 mg plus hydralazine 75 mg three times daily as tolerated.
One or two tablets (acetaminophen 300 mg/codeine 30 mg per tablet) orally every 4-6 hours as needed for pain; maximum 12 tablets daily.
Hydralazine: 2-4 hours (fast acetylators), 4-8 hours (slow acetylators); isosorbide dinitrate: 1 hour (parent), 4-5 hours (isosorbide-5-mononitrate, active metabolite). Clinical context: Requires twice-daily dosing for sustained effect.
Acetaminophen: 2–3 hours (prolonged in hepatic impairment). Codeine: 2.5–3.5 hours; metabolites: morphine 1.5–2.5 hours, codeine-6-glucuronide 3–4 hours. Clinical context: dosing interval every 4–6 hours.
Isosorbide dinitrate: extensively metabolized by denitration and conjugation in the liver; hydralazine: primarily metabolized by N-acetylation (N-acetyltransferase 2, NAT2) and subsequent glucuronidation.
Acetaminophen: primarily glucuronidation and sulfation in liver; minor CYP450 (CYP2E1) to toxic NAPQI. Codeine: CYP2D6 to morphine; CYP3A4 to norcodeine; glucuronidation.
Hydralazine: 80% renal (as active drug and metabolites, predominantly N-acetylhydralazine and hydralazine pyruvic acid hydrazone); isosorbide dinitrate: renal (metabolites, primarily isosorbide mononitrates and isosorbide) and fecal (minor).
Acetaminophen: renal elimination of conjugated metabolites (glucuronide 60%, sulfate 30%, cysteine/mercapturate <5%), less than 5% unchanged. Codeine: renal elimination of codeine (5–15%), morphine (5–10%), norcodeine (10–20%), and conjugates; 90% excreted in urine within 24 hours.
Hydralazine: 87-90% (plasma proteins); isosorbide dinitrate: 30-40% (albumin).
Acetaminophen: 10–25% (albumin). Codeine: 7–25% (primarily albumin).
Hydralazine: 1.6 L/kg; isosorbide dinitrate: 2-4 L/kg. Clinical meaning: Extensive tissue distribution for both components.
Acetaminophen: 0.9 L/kg. Codeine: 3–6 L/kg (extensive tissue distribution).
Hydralazine: 30-50% (oral, first-pass effect); isosorbide dinitrate: 20-30% (oral, extensive first-pass metabolism).
Oral: acetaminophen 88% (variable first-pass); codeine 50–60% (first-pass metabolism to morphine, norcodeine, and conjugates).
No specific dose adjustment recommended; however, hydralazine is cleared renally and may accumulate in severe renal impairment (Cr Cl <30 m L/min); consider monitoring for adverse effects.
GFR 30-50 m L/min: administer every 6 hours; GFR 10-29 m L/min: administer every 8 hours; GFR <10 m L/min: administer every 12 hours; hemodialysis: not recommended.
Contraindicated in severe hepatic impairment (Child-Pugh class C). In mild to moderate impairment (Child-Pugh A or B), no specific dose adjustment but caution advised due to potential increased exposure.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50% and extend interval to every 8 hours; Child-Pugh C: contraindicated.
Safety and efficacy not established in pediatric patients; no standard dosing recommendations available.
For children ≥12 years: acetaminophen 10-15 mg/kg/dose and codeine 0.5-1 mg/kg/dose orally every 4-6 hours; maximum acetaminophen 75 mg/kg/day, codeine 6 mg/kg/day. For children <12 years: not recommended due to codeine safety concerns.
Initiate at lower end of dosing range; titrate slowly due to increased risk of hypotension and dizziness; monitor renal function as hydralazine clearance may decrease.
Start with lowest effective dose; acetaminophen component maximum 3 g/day; consider reduced codeine dose (e.g., 15 mg) due to increased sensitivity and risk of respiratory depression; extend dosing interval to every 6-8 hours.
None.
Risk of medication errors: confusion between milligram and milliliter doses, and between codeine and acetaminophen components. Contraindicated for postoperative pain management in children following tonsillectomy/adenoidectomy due to risk of respiratory depression and death.
Hypotension (monitor blood pressure), agranulocytosis (rare; hydralazine may cause neutropenia; monitor CBC), drug-induced lupus-like syndrome (hydralazine; discontinue if symptoms develop), hepatotoxicity (hydralazine; monitor liver enzymes), risk of syncope when initiating or increasing dose, volume depletion (correct before use).
Hepatotoxicity (acetaminophen overdose); respiratory depression; drug dependence; ultra-rapid metabolizers of codeine (CYP2D6) leading to morphine toxicity; concomitant CNS depressants; use in pediatric patients; avoid alcohol.
Hypersensitivity to hydralazine or isosorbide dinitrate, severe hypotension (<100 mm Hg systolic), acute myocardial infarction (safety not established), cardiogenic shock, cardiomyopathy with restrictive/obstructive physiology, use with phosphodiesterase-5 inhibitors (e.g., sildenafil, tadalafil) due to risk of severe hypotension.
Hypersensitivity to acetaminophen or codeine; severe respiratory depression; acute or severe asthma; paralytic ileus; post-operative pain management in children after tonsillectomy/adenoidectomy; breastfeeding (in ultra-rapid metabolizers); concomitant MAOIs.
No specific food interactions. Avoid excessive alcohol intake as it may exacerbate hypotension.
Avoid alcohol; high-fat meals may delay absorption but not clinically significant.
FDA Pregnancy Category C. First trimester: Animal studies show fetal harm; no adequate human studies. Second and third trimesters: Hydralazine crosses placenta; may cause fetal hypotension, thrombocytopenia. Isosorbide dinitrate: Limited data; associated with methemoglobinemia in neonates. Use only if benefit outweighs risk.
Acetaminophen is considered low risk in all trimesters at therapeutic doses; chronic high doses may be associated with adverse outcomes. Codeine is associated with risk of respiratory depression and neonatal withdrawal if used near term; may cause neural tube defects and other malformations with first-trimester exposure, but data are conflicting. Use lowest effective dose for shortest duration.
Hydralazine is excreted in breast milk (M/P ratio ~1.2); low levels unlikely to harm infant. Isosorbide dinitrate: No data on excretion. Monitor infant for hypotension. American Academy of Pediatrics considers hydralazine compatible with breastfeeding.
Acetaminophen is excreted into breast milk in low amounts (M/P ratio ~0.91-1.42) and is considered compatible with breastfeeding. Codeine is also excreted in breast milk; risk of infant opioid toxicity depends on maternal CYP2D6 phenotype. Ultra-rapid metabolizers may produce higher morphine levels. Use with caution, avoid in known CYP2D6 ultra-rapid metabolizers, and monitor infant for sedation and respiratory depression.
Pregnancy may increase volume of distribution and clearance of hydralazine; dose adjustments may be needed to maintain efficacy. Isosorbide dinitrate: no specific recommendations; start at lowest effective dose and titrate based on blood pressure response. Monitor for orthostatic hypotension.
No routine dose adjustment needed for acetaminophen. Codeine pharmacokinetics are altered in pregnancy: increased clearance and volume of distribution may require dose adjustment; however, due to variability in CYP2D6 metabolism, individualize dosing and monitor for efficacy and toxicity. Avoid codeine in pregnancy unless alternative analgesics are ineffective.
Bidil is a fixed-dose combination of isosorbide dinitrate (20 mg) and hydralazine (37.5 mg), indicated as an adjunct to standard therapy for heart failure in self-identified African American patients (NYHA class III-IV, left ventricular ejection fraction <45%). Dizziness and headache are common due to vasodilation; titrate slowly. Avoid use with phosphodiesterase-5 inhibitors (e.g., sildenafil) due to risk of severe hypotension. Monitor for fluid retention and worsening heart failure. Consider dose reduction in hepatic impairment.
For acute pain, limit codeine to 3 days; avoid in children under 12 due to CYP2D6 ultra-rapid metabolizer risk of fatal respiratory depression; monitor for constipation; assess liver function for acetaminophen hepatotoxicity; use with caution in renal impairment.
Take this medication exactly as prescribed, usually three times daily with or without food.,Do not take with erectile dysfunction drugs (e.g., Viagra, Cialis, Levitra) as this can cause a dangerous drop in blood pressure.,Common side effects include dizziness and headache, which may improve over time; report severe or persistent symptoms to your doctor.,Avoid sudden position changes to prevent falls.,Do not stop taking this medication abruptly without consulting your healthcare provider.,Inform all healthcare providers you are taking Bidil.,Store at room temperature, away from moisture and heat.
Take exactly as prescribed; do not exceed 4000 mg acetaminophen per day.,Avoid alcohol while taking this medication.,Do not use with other acetaminophen-containing products.,May cause dizziness or drowsiness; avoid driving until you know how you react.,Common side effects include constipation, nausea, and drowsiness.,Seek emergency if signs of allergic reaction or difficulty breathing occur.
No interactions on record
"Pirenzepine, a selective M1 muscarinic antagonist, reduces gastrointestinal motility and secretions, while codeine, an opioid agonist, also decreases gastrointestinal motility via mu-opioid receptors. Concurrent use leads to additive anticholinergic and opioid effects, resulting in enhanced risk of severe constipation, paralytic ileus, and central nervous system depression. Clinically, patients may experience exacerbated sedation, respiratory depression, and urinary retention."
"Ropinirole, a non-ergoline dopamine agonist used in Parkinson's disease and restless legs syndrome, may reduce the analgesic efficacy of codeine. This is likely due to pharmacodynamic antagonism at central dopamine and opioid receptors, as well as potential pharmacokinetic interactions that decrease the conversion of codeine to its active metabolite morphine via CYP2D6 inhibition by ropinirole. The resultant blunted opioid response can lead to inadequate pain control, necessitating dose adjustment or alternative therapy."
"Vemurafenib induces CYP3A4, significantly reducing the plasma concentrations of codeine, which is metabolized via CYP3A4 to its active metabolite morphine. This may diminish codeine's analgesic efficacy, potentially leading to inadequate pain control. Additionally, reduced formation of morphine may lower the risk of opioid-related adverse effects."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BIDIL vs ACETAMINOPHEN AND CODEINE PHOSPHATE, answered by our medical review team.
BIDIL is a Vasodilator Combination that works by Combination of isosorbide dinitrate (a nitric oxide donor) and hydralazine (a direct vasodilator). Isosorbide dinitrate relaxes vascular smooth muscle via NO-mediated c GMP production; hydralazine reduces peripheral resistance and may inhibit DNA synthesis in endothelial cells. Synergy enhances vasodilation and improves cardiac output.. ACETAMINOPHEN AND CODEINE PHOSPHATE is a Opioid Agonist that works by Acetaminophen: centrally acting analgesic and antipyretic, possibly via inhibition of cyclooxygenase (COX) and modulation of cannabinoid receptors. Codeine: prodrug converted to morphine; mu-opioid receptor agonist.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BIDIL and ACETAMINOPHEN AND CODEINE PHOSPHATE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BIDIL is: Isosorbide dinitrate 20 mg plus hydralazine 37.5 mg orally three times daily; titrate to target dose of isosorbide dinitrate 40 mg plus hydralazine 75 mg three times daily as tolerated.. The standard adult dose of ACETAMINOPHEN AND CODEINE PHOSPHATE is: One or two tablets (acetaminophen 300 mg/codeine 30 mg per tablet) orally every 4-6 hours as needed for pain; maximum 12 tablets daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BIDIL and ACETAMINOPHEN AND CODEINE PHOSPHATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BIDIL is classified as Category C. FDA Pregnancy Category C. First trimester: Animal studies show fetal harm; no adequate human studies. Second and third trimesters: Hydralazine crosses placenta; may cause fetal hyp. ACETAMINOPHEN AND CODEINE PHOSPHATE is classified as Category D/X. Acetaminophen is considered low risk in all trimesters at therapeutic doses; chronic high doses may be associated with adverse outcomes. Codeine is associated with risk of respirat. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.